---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-107821"
form_type: "8-K"
ticker: "NKTR"
cik: "0000906709"
company_name: "NEKTAR THERAPEUTICS"
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:49:49.580266+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Nektar reports REZOLVE-AD Phase 2b data showing asthma improvements with rezpegaldesleukin

## Summary
- Respegaldesleukin achieved statistically significant ACQ-5 reductions vs placebo in patients with AD and asthma (p<0.05).
- In uncontrolled asthma subset (ACQ-5≥1.5, n=25), all doses showed significant ACQ-5 improvement; placebo-adjusted reductions 1.0–1.4.
- Placebo crossover (n=42) at week 24: EASI-75 60%, vIGA-AD 0/1 33%, EASI-90 37%, Itch NRS response 50%.
- Data support 24 μg/kg q2w dose with 24-week induction period for Phase 3 studies.
- Top-line Phase 2b data in alopecia areata expected December 2025.

## SEC filing metadata
- accession: 0001213900-25-107821
- form_type: 8-K
- ticker: NKTR
- cik: 0000906709
- company_name: NEKTAR THERAPEUTICS
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/906709/000121390025107821/0001213900-25-107821-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/906709/000121390025107821/ea0264736-8k_nektar.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-107821
- JSON: https://secwatch.observer/filing/0001213900-25-107821.json
- Plain text: https://secwatch.observer/filing/0001213900-25-107821.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.